more common in patients receiving chronic hemodialysis than in the general population. A carriage rate of 40.5-84.0% has been reported for such patients [4] [5] [6] .
S. aureus is a leading cause of bacteremia among hemodialysis-dependent patients and the rates may be increasing [7] . Persons receiving hemodialysis are especially vulnerable to vascular access infections because they require vascular access for prolonged periods and undergo frequent puncture of their vascular access site. Vascular access is a major risk factor for bacteremia [4, 8] , infection-related hospitalization and mortality among hemodialysis patients because of their immunodeficiency [1] . Complications of S. aureus bacteremia include sepsis, endocarditis, osteomyelitis, septic arthritis, peritonitis and metastatic abscesses [9, 10] . On the other hand, hemodialysis patients undergoing long-term hemodialysis, recurrent antimicrobial treatment and immunodeficiency cause increased bacterial resistance and the spread of dangerous hospital infections to other patients. There are many studies [4] [5] [6] showing a high incidence rate of staphylococcal carriage in hemodialysis patients, and these carriages are known to be the main risk factor for spreading hospital infections. Therefore, study of the prevalence rate of staphylococcal carriage and drug resistance patterns in staphylococcal isolates can help in determining the rate of infection in order to manage S. aureus carriage and prevent serious consequences, including mortality in either hemodialysis patients or others.
Although there are some reports of nasal carriage rates among hospital patients other than those undergoing hemodialysis and also on health care workers in our region [8, 11] , very little information is available on the prevalence rate of nasal carriage in hemodialysis patients in Iran. Thus, in this cross-sectional study, we aimed to determine the frequency of S. aureus nasal carriage in hemodialysis patients in Shiraz, the major city in southwestern Iran, and to investigate the resistance patterns of the isolated S. aureus against various antibiotics used broadly for treatment.
Subjects and Methods
This study was conducted in Faghihi Hospital, a referral dialysis center in Shiraz, Iran. Shiraz is the largest city in the southwest of Iran. Faghihi University Hospital in Shiraz serves as a referral center with more than 10,000 admissions per year.
In a cross-sectional study from May to September 2007, 130 hemodialysis patients who had undergone treatment for at least 12 months were included. Of the 130 patients, 49 were females and 81 were males; mean age was 55.5 8 15.2 years. The patients who had undergone ! 12 months hemodialysis were excluded. Nasal and skin specimens were collected from the hemodialysis patients using 2 cotton-wool swabs for each patient.
Cotton-wool sterile swabs were moistened in normal saline and were rotated in the left and right anterior nares. Skin swabs were obtained from a 3 ! 3 cm area around the site of access for hemodialysis, before skin preparation. The swabs were immediately inoculated onto sheep blood-agar plates and phenol redmannitol-salt agar (Himedia, India). The plates were incubated at 37 ° C for 48 h and identification of S. aureus was based upon colony morphology, catalase positivity, mannitol fermentation, Gram-positive cocci in clusters on the tube-coagulase test, clumping factor reaction with rabbit plasma on microscope slides, and DNase positivity [12] .
The susceptibility of strains to antibacterial agents was determined by using the Kirby-Bauer disc diffusion method (the predominant method employed in Iran), following the guidelines of the Clinical and Laboratory Standards Institute [13] . Each isolate was tested using the following panel of antibiotic discs (Mast Diagnostics, UK) including vancomycin (30 g), rifampin (5 g), ciprofloxacin (5 g), tetracycline (10 g), methicillin (5 g) and erythromycin (15 g ). The standard sensitive strain of S. aureus ATCC 25923 was included as a control for reproducibility of results with every batch of antibiotic sensitivity test.
Owing to the high risk of staphylococcal infections in hemodialysis patients, those isolates showing intermediate susceptibility to an antimicrobial agent were categorized as resistant isolates for data analysis and presentation.
The results were statistically analyzed and the groups were compared by 2 tests using SPSS, version 11.5. Differences between groups were considered statistically significant if p ! 0.05.
Results
32 (24.6%) patients were identified as S. aureus nasal carriers (95% CI 17.5-32.9%). There was no significant difference between male and female nasal carriers. The lowest and the highest prevalence rates of nasal carriage were observed in the 20-to 30-year and the 71-to 80-year age groups, respectively, and the difference was statistically significant (p ! 0.05). Age and gender distributions of S. aureus nasal carriers are presented in table 1 . S. aureus was also isolated from skin of 5 (3.8%) patients who were nasal carrier as well: 3 males and 2 females.
Based on clinical reports, among the 32 nasal carriers; 15 (53.6%) had a past history of hypertension, 4 (14.3%) of insulin-dependent diabetes mellitus, 3 (10.7%) of both diabetes and hypertension, and 6 (21.2%) of renal dysfunctions. No significant association was detected between S. aureus nasal carriage and having a past history of hypertension, diabetes mellitus or renal dysfunctions.
The prevalence of antibacterial sensitivities in 37 isolated S. aureus is given in table 2 . The highest susceptibility results were observed against vancomycin, rifampin and ciprofloxacin, and the lowest ones were against methicillin and erythromycin.
Discussion
S. aureus , a frequent cause of infections in both the community and hospital, is the most common organism responsible for intravenous catheter-related infection, postoperative wound infection, septicemia, septic arthritis, and skin and soft tissue endogenous infections in hemodialysis patients [7, 9, 10, 14, 15] . A major part of dialysis-related infection is endogenous and related to the high frequency of nasal and skin carriage of S. aureus [16] . The nose is the main ecological niche where S. aureus resides in human beings, but the determinants of the carrier state are incompletely understood. It has been shown that nasal carriers of S. aureus have an increased risk of acquiring an infection with this pathogen. Eradication of S. aureus from nasal carriers prevents infection in specific patient categories, including hemodialysis patients [17] . Worldwide, the increasing resistance of this pathogen to various antibiotics complicates treatment of S. aureus infections. Therefore, effective measures to prevent S. aureus infections are urgently needed.
In the present study, a mean S. aureus carriage rate of 24.6% was observed. However, this rate is lower than those reported in other studies (40.5-84.0%) [4] [5] [6] . The difference between the lower prevalence rate observed in our study and those of other studies may be partly due to differences in the quality of sampling and to the culture techniques used in different studies. For example, in a study in northeastern Iran with a smaller sample, 40.5% of 69 hemodialysis patients were reported to have S. aureus in their nose [6] . Some studies reported that when patients were hospitalized, insulin-dependent diabetes mellitus, hemodialysis treatment, intravenous drug addiction, S. aureus skin infections and HIV infection increased carriage rates significantly [1, 3] .
The higher prevalence rate in older patients ( 1 71 years) in our study confirmed the finding that older age was associated with the risk of S. aureus nasal carriage [16] [17] [18] . Further, Saxena and Panhotra [16] reported that patients 1 65 years had a significantly higher prevalence of nasal carriage of S. aureus and carried an approximately 12.5 times greater combined risk of developing S. aureus -and vascular access-related septicemia than the youngest age group. These findings might be helpful in the identification of elderly hemodialysis patients as a high-risk group for S. aureus -linked vascular access-related septicemia and to develop appropriate preventive strategies.
In our study, male patients had a higher prevalence of S. aureus nasal carriage, but no significant difference was detected between male and female subjects. Similarly, gender was not considered as an important risk factor for S. aureus carriers in hemodialysis patients in another study [19] .
No significant association was detected between S. aureus nasal carriage and having a past history of hypertension, diabetes mellitus or renal dysfunctions. Similarly, a study reported that diabetes mellitus was not a significant risk factor for nasal carriage [19] . However, there are some researchers reporting insulin-dependent diabetes mellitus as an increasing factor for S. aureus carriage rates [1, 3] . Several oral and topical antibiotics for eradication of S. aureus nasal carriage in hemodialysis patients have been studied [8] . Similar to some other studies [20, 21] , we found high levels of resistance to tetracycline, methicillin and erythromycin. In our study, more than half of the S. aureus isolates were methicillin-resistant S. aureus (MRSA). In a study in another hospital of Shiraz, MRSA nasal carriage rate was reported to be 42.4% among hospital patients [11] , which is more than that observed in our study. However, one study has shown that the rates of MRSA isolates have increased steadily over the past decade [15] . Most of our isolates were sensitive to vancomycin, rifampin and ciprofloxacin. Rifampin has been shown to be the most effective oral agent used for S. aureus eradication [4] . Kluytmans et al. [17] showed that mupirocin nasal ointment effectively eliminated nasal carriage of S. aureus in patients on hemodialysis, but a steadily increasing resistance to mupirocin has been reported in Kuwaiti hospitals in recent years [20] .
Smith et al. [22] reported that vancomycin was the only uniformly effective treatment for staphylococcal infections, although reduced susceptibility to vancomycin has also recently been reported [15] .
In this study, carrier status was based only on a single culture, which does not differentiate permanent carriers from intermittent carriers. However, there is increasing evidence showing that higher numbers of staphylococci constitute a higher risk of infections by the patients' own strain in permanent carriers.
In our study the nasal carriage rates of S. aureus in dialysis patients were less than in some other studies [4] [5] [6] ; however, as even a low rate of staphylococcal nasal carriage is of significance, precise screening of the S . aureus carrier state in hemodialysis patients, including the antibiotic sensitivity test if possible, is vital to adequately target prevention strategies (such as using nasal ointments). Other measures of prevention (e.g. vaccines for staphylococcal infections) can be considered, as a conjugate vaccine in hemodialysis patients has been shown to confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease [23] .
Conclusion
The nasal carriage rate of S. aureus observed in dialysis patients in this study was relatively high, so screening of the S . aureus carrier state in our hemodialysis patients for prompt prevention strategies is recommended. No vancomycin-resistant S. aureus was observed in our study. However, continued determination of the emergence of glycopeptide-resistant isolates of S. aureus remains a prudent strategy.
